Human Growth Hormone

Human Growth Hormone

• Home
• What is HGH?
• Search
• Syndicate
• More Health

See Also

Human Growth Hormone > Nutropin > Cambridge

Please select a HGH news story from the list below:

• Business Wire - SG Cowen Global Health Care Conference to Webcast Alkermes' Corporate Presentation
• Biotech Financial Reports - ALKERMES REPORTS BIG DECREASE IN NET LOSS FOR FISCAL YEAR.(Brief Article)(Statistical Data Included)
• Business Wire - Genentech Corrects and Replaces Previous Genentech and Alkermes Announcment, BW0172 CA-GENENTECH/ALKERMES
• M2 Presswire - Nutropin Depot, first long-acting dosage form of recombinant growth hormone, now available.
• Business Wire - Nutropin Depot, First Long-Acting Dosage Form of Recombinant Growth Hormone, Now Available
• M2 Presswire - US FDA: FDA approves Nutropin Depot, first lo long-acting dosage form of recombinant growth hormone.
• M2 Presswire - GENENTECH: Genentech & Alkermes announce submission of drug application with the FDA for Nutropin Depot.
• Business Wire - Phase III Clinical Trial Shows Promising Results of Nutropin Depot; First Long-Acting Formulation of Recombinant Growth Hormone
• M2 Presswire - GENETECH: Phase III clinical trial shows promising results of Nutropin Depot.
• Chemical Market Reporter - GENETECH.(Genetach Inc. will file application for new drug with Federal Drug Administration )

Business Wire - SG Cowen Global Health Care Conference to Webcast Alkermes' Corporate Presentation

November 21, 2001 -- Business Editors & Health/Medical Writers CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 21, 2001 Alkermes, Inc. (NASDAQ: ALKS) announced today that its...

• Business Wire - SG Cowen Global Health Care Conference to Webcast Alkermes' Corporate Presentation

Biotech Financial Reports - ALKERMES REPORTS BIG DECREASE IN NET LOSS FOR FISCAL YEAR.(Brief Article)(Statistical Data Included)

July 1, 2001 -- Alkermes, Inc. (NASDAQ:ALKS), Cambridge, Mass., has reported that the net loss for the fiscal year ended March 31 2001 was $16.9 million as...

• Biotech Financial Reports - ALKERMES REPORTS BIG DECREASE IN NET LOSS FOR FISCAL YEAR.(Brief Article)(Statistical Data Included)

Business Wire - Genentech Corrects and Replaces Previous Genentech and Alkermes Announcment, BW0172 CA-GENENTECH/ALKERMES

January 8, 2001 -- Business Editors NOTE: The following news release replaces and corrects the previous Genentech news release, which ran earlier Monday on...

• Business Wire - Genentech Corrects and Replaces Previous Genentech and Alkermes Announcment, BW0172 CA-GENENTECH/ALKERMES

M2 Presswire - Nutropin Depot, first long-acting dosage form of recombinant growth hormone, now available.

June 29, 2000 -- M2 PRESSWIRE-29 June 2000-GENENTECH: Nutropin Depot, first long-acting dosage form of recombinant growth hormone, now available (C)1994-2000 M2...

• M2 Presswire - Nutropin Depot, first long-acting dosage form of recombinant growth hormone, now available.

Business Wire - Nutropin Depot, First Long-Acting Dosage Form of Recombinant Growth Hormone, Now Available

June 28, 2000 -- Business Editors and Health/Medical Writers SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass.--(BW HealthWire)--June 28, 2000--Genentech, Inc....

• Business Wire - Nutropin Depot, First Long-Acting Dosage Form of Recombinant Growth Hormone, Now Available

M2 Presswire - US FDA: FDA approves Nutropin Depot, first lo long-acting dosage form of recombinant growth hormone.

December 24, 1999 -- M2 PRESSWIRE-24 December 1999-US FDA: FDA approves Nutropin Depot, first long-acting dosage form of recombinant growth hormone for growth hormone...

• M2 Presswire - US FDA: FDA approves Nutropin Depot, first lo long-acting dosage form of recombinant growth hormone.

M2 Presswire - GENENTECH: Genentech & Alkermes announce submission of drug application with the FDA for Nutropin Depot.

June 29, 1999 -- M2 PRESSWIRE-29 June 1999-GENENTECH: Genentech and Alkermes announce the submission of a new drug application with the FDA for Nutropin Depot...

• M2 Presswire - GENENTECH: Genentech & Alkermes announce submission of drug application with the FDA for Nutropin Depot.

Business Wire - Phase III Clinical Trial Shows Promising Results of Nutropin Depot; First Long-Acting Formulation of Recombinant Growth Hormone

June 14, 1999 -- SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass.--(BW HealthWire) --June 13, 1999-- Genentech, Inc. (NYSE:GNE) and Alkermes, Inc. (Nasdaq:ALKS)...

• Business Wire - Phase III Clinical Trial Shows Promising Results of Nutropin Depot; First Long-Acting Formulation of Recombinant Growth Hormone

M2 Presswire - GENETECH: Phase III clinical trial shows promising results of Nutropin Depot.

June 14, 1999 -- M2 PRESSWIRE-14 June 1999-GENETECH: Phase III clinical trial shows promising results of Nutropin Depot (C)1994-99 M2 COMMUNICATIONS LTD...

• M2 Presswire - GENETECH: Phase III clinical trial shows promising results of Nutropin Depot.

Chemical Market Reporter - GENETECH.(Genetach Inc. will file application for new drug with Federal Drug Administration )

November 2, 1998 -- GENETECH Inc. will proceed with plans early next year to submit a new drug application with FDA for Nutropin Depot, a sustained release formulation...

• Chemical Market Reporter - GENETECH.(Genetach Inc. will file application for new drug with Federal Drug Administration )

Cities

cambridge medical writers cambridge south san francisco

Province/States

california massachusetts